PILA PHARMA AB is a private, Swedish “micro-pharma” aiming at developing innovative new approaches to treat diabetes. PILA PHARMA owns issued use-patents that give the exclusive right to treat diabetes and obesity with antagonists of the TRPV1 receptor. The company has recently acquired the TRPV1 antagonist asset previously owned by Ario Pharma Ltd (Cambridge, U.K.).
This asset includes a series of small molecule TRPV1 antagonists including the clinical ready and safe development candidate XEN-D0501, patents, know-how and data.
The TRPV1 target (also called the “chili-receptor”) has been shown to have applications across pain and inflammatory diseases and is speculated to have a role in diabetes as well.
PILA PHARMA AB is dedicated to bringing the TRPV1 antagonist, a truly innovative oral anti-diabetes product closer to the market. And in addition to our current research collaborations, we intend to finance the development of our pre-clinical candidate through partnering, venture capital, corporate funds and/or grants.